Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo ; volume:23 ; number:1 ; day:31 ; month:10 ; year:2023 ; pages:1-10 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (31.10.2023), 1-10, 12.2023
- Urheber
-
Kayano, Taishi
Nishiura, Hiroshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08748-1
- URN
-
urn:nbn:de:101:1-2024011721103299176554
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kayano, Taishi
- Nishiura, Hiroshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2